Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Corbus Pharmaceuticals announced it will host a conference call on Monday, September 14, 2026 at 8:00 a.m. EDT to discuss topline data from CANYON-1, a Phase 1b study of its obesity drug candidate CRB-913. Study investigator Harold Bays, M.D. will be a guest speaker.
Key figures
- Dose cohorts
- ["20 mg","40 mg","60 mg"]
- Call datetime
- Monday, September 14, 2026, 8:00 a.m. EDT
- Randomization
- 1:1:1:1 vs placebo
- Study participants
- 240
- Dosing period weeks
- 12
- Trial duration weeks
- 16
- Safety followup weeks
- 4
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.